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Abstract  1 
This study aimed at evaluating non-starter lactobacilli (NSLAB) isolated from cheeses for their 2 
proteolytic activity and capability to produce fermented milk enriched in angiotensin-converting 3 
enzyme (ACE)-inhibitory and antioxidant peptides. Preliminarily, 34 NSLAB from Parmigiano 4 
Reggiano (PR) and 5 from Pecorino Siciliano cheeses were screened based on their capacity to 5 
hydrolyze milk proteins. Two NSLAB strains from PR, Lactobacillus casei PRA205 and 6 
Lactobacillus rhamnosus PRA331, showed the most proteolytic phenotype and were positively 7 
selected to inoculate sterile cow milk. The fermentation process was monitored by measuring viable 8 
cell population, kinetic of acidification, consumption of lactose, and synthesis of lactic acid. Milk 9 
fermented with Lb. casei PRA205 exhibited higher radical scavenging (1184.83 ± 40.28 mmol/L 10 
trolox equivalents) and stronger ACE-inhibitory (IC50 = 54.57 μg/mL) activities than milk 11 
fermented with Lb. rhamnosus PRA331 (939.22 ± 82.68  mmol/L trolox equivalents; IC50= 212.38 12 
μg/mL). Similarly, Lb. casei PRA205 showed the highest production of ACE-inhibitory peptides 13 
Val-Pro-Pro and Ile-Pro-Pro, which reached concentrations of 32.88 and 7.52 mg/L after 87 and 96 14 
h of milk fermentation, respectively. This evidence supports Lb. casei PRA205, previously 15 
demonstrated to possess characteristics compatible with probiotic properties, as a promising 16 
functional culture able to promote health benefits in dairy foods. 17 
 18 
Keywords: Lactobacillus, bioactive peptides, valine-proline-proline (VPP), isoleucine-proline-19 
proline (IPP), probiotic, ACE-inhibition 20 
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1. Introduction 22 
Biologically active peptides derived from food proteins are specific protein fragments that have a 23 
positive impact on body functions, going well beyond their nutritional value (Kamau et al., 2010). 24 
Milk proteins, especially caseins, are currently the main precursors of biologically active peptides 25 
(Silva and Malcata, 2005). Depending on size and amino acid sequence, milk-derived peptides may 26 
exert a number of different activities in vitro and/or in vivo, such as immuno-modulation, anticancer 27 
action, hypocholesteremic effect, as well as antimicrobial, mineral-binding, opioid, and peptidase 28 
inhibition activities (Fitzgerald and Murray, 2006; Mills et al., 2011). They can be released from 29 
milk proteins by gastro-intestinal (GI) digestion or by enzymatic hydrolysis during food processing 30 
and fermentation (Pihlanto, 2006). In particular, milk protein hydrolysates and fermented dairy 31 
products are enriched in antihypertensive and antioxidant peptides (Silva and Malcata, 2005; 32 
Pihlanto, 2006; Korhonen, 2009). Among these, lacto-tripeptides valine-proline-proline (VPP) and 33 
isoleucine-proline-proline (IPP) are resistant to GI digestion and can cross the mucosal barrier, 34 
resisting to digestion by serum peptidases (Foltz et al, 2008). VPP and IPP have been shown to 35 
reduce systolic blood pressure in hypertensive subjects (Boelsma and Kloek, 2010; Nakamura et al., 36 
2011; Cicero et al., 2013), due to inhibition of angiotensin-converting enzyme (ACE), stimulation 37 
of vasodilator production, and modulation of sympathetic nervous activity (Usinger et al., 2010). In 38 
addition to antihypertensive effects, milk-derived peptidic fractions have been demonstrated to exert 39 
radical scavenging functionalities and prevent oxidative stresses associated with numerous 40 
degenerative chronic diseases, including cardiovascular ischemia, reperfusion, and atherosclerosis 41 
(Kudoh et al., 2001; Virtanen et al., 2007). 42 
Proteolytic systems from lactic acid bacteria (LAB) are the main route to generate bioactive 43 
peptides during milk fermentation and cheese ripening (Gobbetti et al., 2004). LAB possesses 44 
variable patterns of proteinases, peptidases and peptide transport systems which affect release and 45 
intake of bioactive peptides in milk in a species- and strain-specific manner (Liu et al., 2010). These 46 
systems enable LAB to fulfill their amino acid requirements (Christensen et al., 1999) and 47 
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contribute to the formation of flavor and texture in dairy products (Settanni and Moschetti 2010). 48 
Cell-envelope proteases break down proteins in the growth media into peptides of about 5–30 49 
amino acids that are carried into the cell and further hydrolysed by endopeptidases into smaller 50 
peptides and amino acids for microbial protein synthesis. PepI, PepP, PepQ, PepR, and PepX 51 
endopetidases have proline-specific hydrolytic activities which account for the main release of 52 
bioactive peptides from proline-rich α-, β- and κ-caseins. 53 
Lactobacillus genus is predominant in dairy food and encompasses the main acid-producing starter 54 
cultures (SLAB), as well as the mesophilic species most responsible for cheese ripening (indicated 55 
as non-starter LAB, NSLAB). The role of SLAB lactobacilli in bioactive peptide release is well 56 
documented during milk fermentation (reviewed by Gobbetti et al., 2004; Fitzgerald and Murray, 57 
2006). Among SLAB, thermophilic Lactobacillus helveticus and Lactobacillus delbrueckii ssp. 58 
bulgaricus strains have been extensively studied for their strong and specific proteolytic activity in 59 
milk which results in release of higher amount of active peptides compared to other lactobacilli 60 
(Sadat-Mekmene et al., 2011 and references herein). In contrast, a few of works deals with the 61 
ability of mesophilic NSLAB strains to hydrolyze caseins into bioactive peptides (Fuglsang et al., 62 
2003; Ramchandran and Shah, 2008; Wang et al., 2010). Within NSLAB, facultatively 63 
heterofermentative Lactobacillus casei, Lactobacillus paracasei, and Lactobacillus rhamnosus are 64 
extensively used both as probiotics and adjunct cultures in different dairy products (Settanni and 65 
Moschetti, 2010; De Vos, 2011). Potential health benefits associated with the consumption of these 66 
bacteria rely on their ability to interact with the intestinal epithelial cells directly, but also indirectly, 67 
through the production of biogenic compounds (Lebeer et al., 2010 and references herein). When 68 
probiotics are delivered with fermented dairy products, milk-derived peptides with different 69 
biological activities can be produced (Fitzgerald and Murray, 2006; Hayes et al., 2007). 70 
In our previous works, we established a de-replicated set of Lb. casei, Lb. paracasei, and Lb. 71 
rhamnosus NSLAB strains isolated from Parmigiano Reggiano cheese (Solieri et al., 2012) and 72 
assessed their probiotic aptitude (Solieri et al., 2014). Aim of this work was to explore the potential 73 
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of these strains to release bioactive peptides with radical scavenging and ACE-inhibitory activities 74 
during cow milk fermentation, with a special focus on their ability to release VPP and IPP from 75 
milk caseins. 76 
 77 
2. Materials and methods 78 
2.1 Materials 79 
All MS/MS reagents were from Biorad (Hercules CA, U.S.A.), whereas the remaining chemicals 80 
were purchased from Sigma-Aldrich (Milan, Italy) unless otherwise stated. De Man, Rogosa and 81 
Sharpe (MRS) medium was provided by Oxoid (Basingstoke, Hampshire, England). Amicon Ultra-82 
0.5 regenerated cellulose filters with a molecular weight (MW) cut-off of 3 kDa were supplied by 83 
Millipore (Milan, Italy). Ultra-high-temperature-treated (UHT) skimmed bovine milk was obtained 84 
from a local producer (protein, 3.15%; fat, 0.3%; lactose, 4.95%). VPP and IPP peptides (95% 85 
purity) were synthesized by DBA (Milan, Italy). The absorbance was read using a Jasco V-550 86 
UV/Vis spectrophotometer (Orlando FL, U.S.A.), with the exception of DNA samples that were 87 
quantified by Nanodrop ND-1000 Spectrophotometer (Wilmington, DE, USA). Taq DNA 88 
polymerase was from Takara (Kyoto, Japan), while primers were provided by MWG (Heidelberg, 89 
Germany). 90 
 91 
2.2 Bacteria and growth conditions 92 
The bacterial strains used in this study are listed in Table 1. Thirty-four strains were isolated from  93 
ripened Parmigiano Reggiano cheeses (Solieri et al., 2012) and deposited in the Unimore Culture 94 
Collection (UMCC) (www.unimore.umcc.it). Nine Lb. rhamnosus strains isolated from Sicilian 95 
Pecorino cheese and human vaginal samples, were kindly provided by Prof. C. Randazzo 96 
(University of Catania, Italy). All LAB strains were maintained as frozen stock at -80°C in MRS 97 
broth supplemented with 25% glycerol. Prior to the experimental use, the cultures were twice 98 
propagated in MRS medium and incubated at 37°C for 24 h under anaerobic conditions. For 99 
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preliminary screening of NSLAB proteolytic activity, bacterial cells grown until late exponential 100 
phase in MRS medium, were harvested by centrifugation, and washed twice with 50 mmol/L Tris-101 
HCl buffer (pH 6.5) and inoculated, in triplicates, in 10 mL of ultra-high temperature-treated (UHT) 102 
skimmed milk (2% v/v). Negative control was realized by replacing the cell suspension with Tris-103 
HCl buffer. After incubation at 37°C for 72 h in shaking conditions (10 rpm), samples were treated 104 
with 1% trichloroacetic acid (TCA) for 10 min and centrifuged (10,000g, 20 min, 4°C) for 105 
proteolytic activity determination and relative quantification of VPP and IPP. 106 
 107 
2.3 Cow milk fermentation 108 
Fermented milk was produced with the best strains previously chosen in preliminary screening, by 109 
using UHT skimmed milk under sterile conditions in order to exclude enzyme interference by 110 
contaminant microorganisms. Fifty mL of UHT skimmed milk were inoculated with single-strain 111 
cultures of selected LAB strains [2% v/v corresponding to ca. 108 colony forming units (cfu)/mL 112 
final concentration], as reported above, and incubated at 37°C for 120 h in shaking conditions (10 113 
rpm). Three biological replicates were performed for each strain. For each replicate, two aliquots 114 
were taken at 11 time points (0, 15, 24, 39, 48, 63, 72, 87, 96, 111, and 120 h). One aliquot was 115 
immediately used to determine the number of viable cells and the pH, whereas the other one was 116 
frozen for subsequent determinations of sugars, lactic acid, amount of VPP and IPP, as well as 117 
ACE-inhibitory, proteolytic and radical scavenging activities. 118 
 119 
2.4 Microbiological analysis 120 
The number of presumptive viable LAB cells was determined at different time points (0, 15, 24, 39, 121 
63, 87, and 111 h) by plating 10-fold diluted samples of fermented milks on MRS agar. After 122 
incubation at 37°C for 48 h under anaerobic conditions, the number of cfu per mL was counted and 123 
expressed as Log cfu/mL. 124 
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At 63 h of fermentation (corresponding to pH lower than 4.4), 9 colonies for each trial were picked 125 
from the highest dilutions of MRS plates, cultured in MRS broth at 37 °C for 24 h, and subjected to 126 
DNA extraction as described by Ulrich and Hughes (2001), with a few modifications. Briefly, the 127 
complete cellular lysis was obtained by increasing the number of freeze-thaw steps from three to 128 
six. A final treatment with 1.5 μL RNase (10 mg/mL) at 37°C for 30 min was added to assure 129 
complete RNA degradation. DNA was quantified spectrophotometrically and properly diluted. The 130 
V1 region of the Lb. casei 16S rRNA gene and the Lb. rhamnosus 16S–23S rRNA intergenic spacer 131 
region (ISR) were amplified using the species-specific primer pairs Casei/Y2 and PrI/RhaII, 132 
respectively (Solieri et al., 2012). PCR conditions were according to Solieri et al. (2012) with the 133 
following exceptions: annealing temperature was shifted from 55 to 58°C and the final 134 
concentration of template DNA was increased from 2 to 4 ng/µL. Strain genotyping was carried out 135 
through microsatellite primed-PCR (MSP-PCR) using the arbitrarily chosen sequence (GTG)5 (5’-136 
GTG GTG GTG GTG GTG-3’), as previously reported (Solieri e al., 2012). Amplified-fragment 137 
profile comparison in disposable databases (Bionumerics 5.10, Applied Maths, Belgium) was 138 
performed as described by Solieri et al. (2012), using a similarity threshold of 90%. Only 139 
reproducible well-marked amplified fragments were included in gel analysis, faint bands being 140 
ignored. 141 
 142 
2.5 Determination of proteolytic and radical scavenging activities 143 
Aliquots of fermented milk were treated with 1% TCA for 10 min and centrifuged (10,000g, 20 144 
min, 4°C) to obtain TCA-soluble supernatants containing peptide fractions. Proteolytic activity was 145 
quantified by measuring the amount of released amino groups in TCA-soluble supernatants using 146 
TNBS method (Adler-Nissen, 1979). A calibration curve was prepared using leucine as standard 147 
(range 0.1–2.0 mmol/L). The results were expressed as mmol/L of leucine equivalents. 148 
The radical scavenging activity of TCA-soluble supernatants was measured using the ABTS method 149 
(Re et al., 1999) and the results were expressed as µmol/L of Trolox.  150 
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 151 
2.6 Chemical analysis 152 
Amounts of lactose, galactose, glucose, and lactic acid were enzymatically determined according to 153 
the manufacturer’s instructions (Megazyme International, Wicklow, Ireland) and the results were 154 
expressed as mmol/L. Samples were centrifuged (10,000g, 20 min, 4°C) and then used for the 155 
analysis. 156 
 157 
2.7 Angiotensin I-converting enzyme (ACE) inhibitory activity 158 
For the ACE-inhibitory activity assay, the peptide fractions were obtained by ultrafiltration to avoid 159 
interference in the assay caused by TCA. Samples (500 µL) collected at 0, 87, 96, 111 and 120 h 160 
were centrifuged (10,000g, 20 min, 4°C) and the supernatant added to an Amicon Ultra-0.5 161 
centrifugal filter with a molecular weight cut-off of 3kDa and centrifuged at 14,000g for 120 min at 162 
4°C. ACE-inhibitory activity of the resulted filtrates was determined spectrophotometrically as 163 
reported by Ronca-Testoni (1983) using the tripeptide, 2-furanacryloyl--phenylalanylglycylglycine 164 
(FAPGG) as substrate, with some modifications. Briefly, 600 µL of FAPGG solution (1.33 mM in 165 
reaction buffer containing 100 mmol/L Tris-HCl, 0.6 mol/L NaCl, pH 8.2), were mixed directly in 166 
cuvette with 100 µL of the same reaction buffer or 100 µL of ultrafiltrated samples. The solution 167 
was kept at 37°C for 3 min before adding 21 µL of ACE solution in order to reach the final enzyme 168 
activity of 50 mU/mL. The reaction was monitored at 345 nm for 10 min. The ACE-inhibitory 169 
activity was calculated as percent of inhibition (ACEi%). The samples with the highest ACE-170 
inhibitory activity were used to calculate the inhibitory power as IC50 (defined as the concentration 171 
of peptides required to inhibit 50% of the enzymatic activity). The IC50 values were determined 172 
using nonlinear regression analysis and fitting the data with the log (inhibitor) vs. response model. 173 
Peptide concentrations correspond to the amount of free amino groups measured with the TNBS 174 
asssay on ultrafiltrated samples as reported above. 175 
 176 
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2.8 Identification and quantification of IPP and VPP 177 
The identification and quantification of IPP and VPP were carried out on 2 µL of suitably diluted 178 
TCA-soluble supernatant through nanoLC-MS/MS experiments performed on a 1200 Series Liquid 179 
Chromatographic two-dimensional system coupled to a 6520 Accurate-Mass Q-TOF LC/MS 180 
(Agilent Technologies, Milano, Italy). Chromatographic separation was performed on a ProtID-181 
Chip-43(II) including a 4 mm 40 nL enrichment column and a 43 mm x 75 µm analytical column, 182 
both packed with a C18 phase (Agilent Technologies). The mobile phase consisted of (A) 183 
H2O/acetonitrile/formic acid (96.9:3:0.1, v/v/v) and (B) acetonitrile/H2O/formic acid (94.9:5:0.1, 184 
v/v/v). The gradient started at 3% B for 0.5 min then linearly ramped up to 11% B in 10 min. The 185 
mobile phase composition was raised up to 40% B in 3 min, then 95% B in 1 min and maintained 186 
for 4 min in order to wash both enrichment and analytical columns. The flow rate was set at 500 187 
nL/min. The mass spectrometer was tuned, calibrated and set with the same parameters as reported 188 
by Dei Più et al. (2014). VPP and IPP were selectively fragmented using a mass to charge ratio of 189 
312.18 and 326.21 (charge +1), respectively. The assignment process was complemented and 190 
validated by the manual inspection of MS/MS spectra. The relative amount of the tri-peptides was 191 
estimated by integrating the area under the peak (AUP) for samples collected during pre-screening. 192 
AUP was measured from the extracted ion chromatograms (EIC) obtained for each peptide. 193 
Absolute quantification of VPP and IPP was carried out in fermented milk samples collected at 0, 194 
39, 48, 63, 72, 87, 96, 111, and 120 h. Calibration curves were constructed as follows. Synthetic 195 
tripeptides IPP and VPP were solubilized at 5 g/L in 0.1 mmol/L potassium phosphate buffer (pH 196 
7.0), and then diluted 1:1000 with solvent A, to obtain the 5 mg/L solution. Subsequent dilutions 197 
were made in the same solvent A to yield, for both the peptides, the following concentrations: 1, 5, 198 
10, 20, 50 and 100 µg/L. Each solution contained the internal standard EGVNDNEEGFFSAR at the 199 
concentration of 50 μg/L. The calibration curves were constructed from the peak area of the peptide 200 
relative to the peak area of the internal standard versus concentration. The concentrations of 201 
tripeptides in fermented milk samples were calculated using the following linear equations: 202 
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y = 6282.4x -109.2 (R2 = 0.9938) 203 
and 204 
y = 12585x -3945 (R2 = 0.9940) 205 
for VPP and IPP, respectively. 206 
 207 
2.9 Statistical analysis 208 
All data were presented as mean ± SD for three replicates for each prepared sample. ANOVA with 209 
Tukey post-hoc test and two way ANOVA with Bonferroni post test were performed using Graph 210 
Pad Prism (GraphPad Software, San Diego, CA). The differences were considered significant with 211 
P <0.05. Correlation and non-linear regression analysis was also performed with Graph Pad Prism. 212 
The correlation, expressed as Pearson r-value, was considered significant when P < 0.05. 213 
 214 
3. Results 215 
3.1 Assessment of proteolytic activity  216 
As preliminary screening, the proteolytic potential of 39 NSLAB strains isolated from dairy sources 217 
(34 from PR and 5 from Sicilian Pecorino cheeses, respectively) and 5 strains isolated from human 218 
samples was tested on milk proteins after 72 h of incubation (Figure 1). Values of leucine 219 
equivalents (mmol/L) were normalized with respect to negative control, which showed a value of 220 
1.22 mmol/L of leucine equivalents at time 0 and, as expected, remained constant until the end of 221 
the experiment (72 h).  222 
As depicted in Figure 1, the extent of proteolysis varied significantly among the strains. Out of 44 223 
analyzed strains, 32 displayed low or absent proteolytic activity. A set of 12 strains, including 11 224 
Lb. rhamnosus and 1 Lb. casei, showed concentrations of released amino groups after 72 h of 225 
incubation in a range from 3.89 to 9.01 mmol/L of leucine equivalents. Milk samples fermented 226 
with these strains underwent coagulation after 24-39 h of fermentation (data not shown). Lb. casei 227 
PRA205 showed the best proteolytic activity (9.01 mmol/L of leucine equivalents) followed by Lb. 228 
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rhamnosus LOC12 (5.42 mmol/L of leucine equivalents) and Lb. rhamnosus PRA331 (5.25 229 
mmol/L of leucine equivalents).  230 
Twelve strains showing the best proteolytic activity were further evaluated for their ability to 231 
release VPP and IPP. The relative amount of VPP and IPP was quantified through nanoLC/MS and 232 
tandem MS experiments and expressed as AUC. As shown in Figure 2, Lb. casei PRA205 and Lb. 233 
rhamnosus PRA331 overcame the other strains in releasing IPP and VPP. On the basis of their 234 
highest proteolytic activity and ability to release IPP and VPP, Lb. casei PRA205 and Lb. 235 
rhamnosus PRA331 were chosen for further characterization. 236 
 237 
3.2 Fermentation process 238 
The selected lactobacilli PRA205 and PRA331 were inoculated into sterile cow milk. Their 239 
fermentative performance was assessed at regular intervals up to 120 h after the inoculum based on 240 
the production of lactic acid as primary metabolite, the consumption of sugars, and the pH decline. 241 
The growth was also assessed by determining viable cell counts. 242 
Kinetics of decrease in pH and increase in lactic acid content are shown in Figure 3 for both 243 
fermentation trials. After inoculum, the values of pH were 6.61 ± 0.02 and 6.57 ± 0.02 in milk with 244 
PRA205 and PRA331, respectively. Strain PRA205 reached pH value of about 4.0 after 72 h of 245 
growth, while PRA331 needed 48 h to get the same value of pH. With the exception of the initial 246 
time, pH values were significantly lower (P < 0.05) for the milk fermented with PRA331 compared 247 
to the milk fermented with PRA205. In both trials the lactic acid concentration reached a plateau 248 
after 63 h (Figure 3) and, starting from the time 39 h, the amount of lactic acid produced by 249 
PRA331 was significantly greater (P < 0.05) than that produced by PRA205. The highest lactic acid 250 
content was reached at the end of fermentation with PRA331 (262.82 ± 8.49 mmol/L) which 251 
showed faster and more intensive acidification than PRA205 (183.29 ± 18.14 mmol/L). According 252 
to pH decline, coagulation started after 24 h in milk inoculated with strain PRA331 and after 39 h in 253 
milk inoculated with strain PRA205. As expected, correlation analysis showed an inverse 254 
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relationship between the decrease in pH and the increase in lactic acid concentrations for both the 255 
fermentation trials (PRA331: r = -0.9553, R2 = 0.9127, P = 0.0008; PRA205: r = -0.9276; R2 = 256 
0.8605; P = 0.0009). 257 
Lactose content decreased during fermentation from 124.22 ± 9.36 mmol/L to 82.53 ± 8.23 mmol/L 258 
for strain PRA205 and from 123.72 ± 7.58 mmol/L to 60.97 ± 10.46 mmol/L for strain PRA331. 259 
Glucose content (about 0.4 mmol/L in both samples immediately after the inoculum) halved in the 260 
first 15 h and remained constant until 120 h after inoculum, whereas galactose content was below 261 
the detection limit of the assay at each sampling time. 262 
The initial value of viable lactobacilli population was about Log 8 cfu/mL for both fermentation 263 
trials. Starting from 63 h, the values of viable cell counts remained constant, with final Log values 264 
of 11.43 cfu/mL and 9.47 cfu/mL for trials inoculated with PRA205 and PRA331, respectively. At 265 
the end of fermentation (corresponding to pH ≤ 4.2 after app. 63 h), colonies grown on the highest 266 
dilution MRS plates were randomly picked and submitted to Lb. rhamnosus- and Lb. casei-specific 267 
PCR assays, as well as to MSP-PCR genotyping. As expected, PCR targeting Lb. rhamnosus 16-268 
23S rRNA intergenic region was positive only for the isolates retrieved from milk inoculated with 269 
PRA331, whereas PCR targeted V1 region of the Lb. casei 16S rRNA gene was positive for those 270 
recovered from milk inoculated with PRA205 (supplementary Table S1). MSP-PCR with primer 271 
(GTG)5 showed that each set of isolates displayed the same MSP-fingerprints of the corresponding 272 
inoculated strain (supplementary Table S1). Both data sets were congruent to confirm the identity 273 
of each inoculated strain during fermentation. 274 
 275 
3.3 Proteolytic and radical scavenging activities 276 
The TCA-soluble peptide fractions of milk samples fermented with either PRA205 or PRA331 were 277 
collected at different times to assess both proteolytic and radical scavenging activities. During milk 278 
fermentation, the proteolysis degree increased reaching the maximum value after 96 h for both trials 279 
(Figure 4A). In particular, strain PRA205 increased significantly (P < 0.05) the proteolytic activity 280 
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between 24 and 39 h of incubation, rising from a value of 1.88 ± 0.12 mmol/L to a value of 6.67 ± 281 
0.75 mmol/L of leucine equivalents. After 39 h the proteolytic activity of strain PRA205 increased 282 
more gradually, reaching a peak corresponding to 13.55 ± 1.41 mmol/L of leucine equivalents at 96 283 
h after inoculum (Figure 4A). Starting from 111 h of incubation, the amount of free amino groups 284 
decreased of 22% (10.64 ± 0.75 mmol/L of leucine equivalents). The value after 120 h of 285 
incubation was not significantly different from the value at 111 h. Strain PRA331 showed a more 286 
gradual increase in proteolytic activity over time than PRA205, reaching the maximum value of 287 
8.75 ± 0.25 mmol/L of leucine equivalents after 96 h of incubation. Then, a significant decrease of 288 
26% in the amount of free amino groups was observed (Figure 4A). After 111 h of monitoring 289 
there were no significant changes in proteolytic activity in milk fermented with PRA331. 290 
Development of radical scavenging activity during milk fermentation was determined through 291 
ABTS assay. As shown in Figure 4B, we found significant differences between strains PRA205 292 
and PRA331 for the radical scavenging activity. Milk fermented with strain PRA205 showed 293 
greater (P < 0.05) radical scavenging activity than that fermented with PRA331 starting from 39 h. 294 
The radical scavenging activity increased in both trials getting to maximum values after 111 h, 295 
when milk fermented by PRA205 exhibited 1184.83 ± 40.28 mmol/L of trolox equivalents, while 296 
that fermented by PRA331 exhibited 939.22 ± 82.68  mmol/L of trolox equivalents. 297 
 298 
3.4 ACE-inhibitory activity 299 
We evaluated the dynamics of ACE-inhibitory activity (ACEi%) in ultrafiltrated peptide fractions 300 
of samples with the highest proteolytic activity (namely samples collected after 87, 96, 111, 120 h 301 
of incubation). In both fermentation trials ACE inhibition activity was observed at each sampling 302 
time (Figure 5). ACEi% values increased with the fermentation time apart from slight fluctuations 303 
at time 111 h for strain PRA205 and 96 h for strain PRA331. Interestingly, milk inoculated with Lb. 304 
casei PRA205 already had approximately 20% ACEi at 0 h. This may be due to the production of 305 
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ACE-inhibitory peptides during the fermentation in pre-culture. The highest ACEi% was observed 306 
after 120 h of incubation both for Lb. casei PRA205 (100ACEi%) and Lb. rhamnosus PRA331 307 
(48ACEi%). Therefore, ACE-inhibitory power was calculated as IC50 on the samples after 120 h of 308 
incubation. Strain PRA205 displayed higher activity (IC50 54.57 µg/mL) than PRA331 (IC50 212.38 309 
µg/mL). 310 
 311 
3.5 VPP and IPP quantification 312 
The results described above indicate that strains PRA205 and PRA331 release peptides with ACE-313 
inhibitory activity from milk. Therefore we determined the concentrations of the antihypertensive 314 
peptides IPP and VPP during fermentation by nano-flow LC with Q-TOF mass spectrometry. 315 
Figure 6 shows the release of VPP (panel A) and IPP (panel B) over time. VPP started to be 316 
detectable after 39 h in both trials and reached a maximum value after 111 h in milk inoculated with 317 
PRA205 (32.88 mg/L) and after 87 h in that fermented with PRA331 (11.87 mg/L). There was a 318 
significant difference between strains in the ability to release VPP, with PRA205 being more able 319 
than PRA331 to produce VPP (Figure 6A). In milk fermented with PRA331, VPP concentrations 320 
decreased strongly starting from 96 h such that, after 120 h of fermentation, the amount of VPP was 321 
about the 40% of the maximum value observed after 87 h.  322 
The trend in IPP release was similar to that observed for VPP (Figure 6B). In milk fermented with 323 
Lb. casei PRA205 the highest IPP concentration was reached after 96 h (7.52 mg/L), thereafter it 324 
remained constant until 111 h of monitoring and then slightly decreased. In milk fermented with 325 
PRA331, the maximum IPP content (3.62 mg/L) was lower compared to PRA205 and was reached 326 
after 87 h of monitoring. After this time, IPP values decreased and, at the end of the fermentation, 327 
IPP amount was about 30% of the maximum value. Based on these results, Lb. casei PRA205 was 328 
able to release higher amount of the antihypertensive tripeptides VPP and IPP than Lb. rhamnosus 329 
PRA331. 330 
 331 
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4. Discussion 332 
Bioactive peptides present in dairy fermented products have attracted increasing attention as natural 333 
compounds with antihypertensive (mainly ACE-inhibitory) and antioxidant properties (Usinger et 334 
al., 2009). To assure their survival in cheese, NSLAB possess sets of hydrolytic enzymes which 335 
contribute to cheese maturation and could have the potential to release bioactive peptides. To test 336 
this potential, the proteolytic activity and the ability to release the ACE-inhibitory tripeptides VPP 337 
and IPP during milk fermentation have been determined in a pool of strains belonging to the most 338 
common facultatively hetero-fermentative species dominant in ripened cheese varieties. Based on 339 
our results, Lb. casei PRA205 and Lb. rhamnosus PRA331 are the most proteolytic strains and so 340 
they are the best candidates to produce fermented milk with antioxidant activity and enriched in 341 
VPP and IPP. 342 
The rate of pH decrease is a parameter indicative of the fermentative performance of a microbial 343 
culture and of the effectiveness of its proteolytic and glycolytic systems to sustain the microbial 344 
growth (Kunji et al., 1996). Under the experimental conditions of this study, both strains PRA205 345 
and PRA331 ended fermentation within 24-39 h, reaching final viable cell populations of 11.4 and 346 
9.5 Log cfu/mL, respectively. Although there is no general agreement in the minimum 347 
concentration of functional cells to achieve therapeutic benefits, these values greatly exceed the 348 
thresholds of 6.0-8-0 Log cfu/mL recommended by several authors (Kurmann and Rasic, 1991; 349 
Lourens-Hattingh and Vilijeon, 2001). Interestingly, strain PRA205 has been proved to possess 350 
antibiotic susceptibility profile and tolerances to different conditions miming single and multiple 351 
stresses occurring during GI transit (Solieri et al., 2014). Lb. casei PRA205 overcomes Lb. 352 
rhamnosus PRA331 in survival after 3h-treatments with both synthetic pancreatic and gastric juices, 353 
as well as in viability after acidic, salt bile, and lysozyme stresses, respectively (Solieri et al., 2014). 354 
The high number of viable PRA205 cells in combination with their in vitro GI resistance suggests 355 
that fermented milk could be effective for in vivo delivering potentially probiotic PRA205 cells. 356 
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The rates of lactose consumption/lactic acid production are parameters closely strain- and species-357 
dependent (Elfahri et al., 2014). Accordingly, the ability to use lactose was different between the 358 
two strains, which in turn influences the amount of lactic acid. Lb. rhamnosus PRA331 exhibits a 359 
more vigorous fermentation than Lb. casei PRA205, resulting in a more pronounced acidification, 360 
production of lactic acid, and reduction in lactose content. The slower trend of acidification in milk 361 
inoculated with PRA205 may represent a technological advantage, allowing caseins to mostly 362 
remain in solution and increasing the release of bioactive peptides.  363 
Proteolytic activity is a desirable feature for LAB exploited in functional foods (De Vuyst and 364 
Leroy, 2007). In both fermented milks, the progressive increasing in the amount of free amino 365 
groups is indicative of proteolytic activity and confirms the ability of strains PRA205 and PRA331 366 
to efficiently utilize milk proteins and to produce peptides which can be accumulated in the 367 
surrounding medium (Donkor, 2007). The extent of proteolysis varied between strains, with 368 
PRA205 showing higher activity than PRA331. Differences in proteolysis could reflect differences 369 
in proteases and peptidases patterns between Lb. casei and Lb. rhamnosus or in their different 370 
transcriptional regulation (Liu et al., 2010).  371 
Several evidences are accumulating that demonstrate the ability of proteolytic Lactobacillus strains 372 
to produce high concentrations of antioxidant peptides in dairy products (López-Fandiño et al., 373 
2006). A radical scavenging peptide derived from κ-casein was isolated in milk fermented by Lb. 374 
delbrueckii ssp. bulgaricus (Kudoh et al., 2001). In addition, Hernandez-Ledesma et al. (2005) 375 
detected moderate anti-radical activity in different fermented milks, but without any direct 376 
relationship between degree of hydrolysis and antioxidant activity, as Lb. helveticus exhibited 377 
highest proteolytic activity but intermediate antioxidant activity. The development of radical 378 
scavenging activity appears to be more strictly dependent on strain and their specific pattern of 379 
proteolytic enzymes (Virtaren et al., 2006). Our data show that peptide fractions of both fermented 380 
milks possessed radical scavenging activity which increased during fermentation in agreement with 381 
the proteolytic trend. At the end of incubation, antioxidant activities in milks fermented with 382 
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PRA205 and PRA331 were approximately 1.2 and 0.9 mmol/L of Trolox equivalents, respectively. 383 
These values were equal or superior to most of the fermented milk samples analysed by Hernandez-384 
Ledesma et al. (2005). 385 
Various types of milk fermented with Lb. helveticus, Lb. bulgaricus ssp. bulgaricus, Lb. 386 
rhamnosus, Lb. acidophilus, and Lc. lactis ssp. cremoris have been shown to contain peptides with 387 
variable ACE-inhibitory activity (Gobbetti et al., 2004). In our study both strains PRA205 and 388 
PRA331 were able to release ACE-inhibitory peptides during milk fermentation. Milk fermented 389 
with Lb. casei PRA205 displayed IC50 value 3.9 times lower than milk fermented by Lb. rhamnosus 390 
PRA331. This difference could reflect different type, quality or concentration of peptides produced 391 
by PRA205 and PRA331, which in turn could be related to cell envelope proteinase/peptidases with 392 
different specificity (Savijoki et al., 2006).  393 
Nejati et al. (2013) obtained IC50 values ranging from 220 and 1750 μg/mL in pH 4.6-soluble 394 
fractions from milk fermented by different lactobacilli. In our experiments, Lb. casei PRA205 395 
showed an IC50 value 4 and 5 time lower than the highest IC50 values described for Lc. lactis 396 
DIBCA2 and Lb. casei FC113, respectively (Nejati et al., 2013). In according to our data, Nejati et 397 
al. (2013) also found Lb. rhamnosus strains less efficient than Lb. casei in release of ACE-398 
inhibitory peptides with IC50 values ranging from 700 to 1500 µg/mL. Anyway, these values are 3 399 
to 7 times higher than the values obtained with Lb. rhamnosus PRA331. Our results are similar than 400 
that found by Muguerza et al. (2006) using Lb. rhamnosus. On the other hand, milk fermented with 401 
Lb. delbrueckii subsp. bulgaricus or Lc. lactis subsp. cremoris showed IC50 values ranging from 8 402 
to 11.2 μg/mL (Gobbetti et al., 2000).  403 
It is difficult to establish a direct link between IC50 values and in vivo antihypertensive effects, as 404 
the digestive stability and bioavailability of peptides are often uncertain. Although a large number 405 
of peptides with ACE-inhibiting in vitro effects are released during milk fermentation, the present 406 
work focused only on tripeptides VPP and IPP, whose antihypertensive effects have been well 407 
demonstrated in several human studies (Cicero et al., 2013). Lb. helveticus releases IPP and VPP 408 
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from milk proteins at IC50 values of 5 μmol/L and 9 μmol/L, respectively (Seppo et al., 2003; 409 
Tuomilehto et al., 2004). However, Butifoker et al. (2007) found high concentrations of IPP and 410 
VPP in cheeses which did not include Lb. helveticus as starter culture, suggesting that other 411 
lactobacilli are capable to produce these tripeptides during cheesemaking. IPP and VPP were also 412 
detected in milk fermented with Lb. acidophilus and Lb. rhamnosus although at lower 413 
concentrations than those found in milk fermented with Lb. helveticus (Muguerza et al., 2006). Our 414 
results showed that Lb. casei PRA205 and Lb. rhamnosus PRA331 are able to release VPP and IPP 415 
from milk caseins, and that strain PRA205 overtakes PRA331 in VPP and IPP production. 416 
Although IPP is present both in κ-casein and in β-casein, the amount of released IPP was generally 417 
lower than VPP (Butifoker et al., 2007). Accordingly, we found the ratio between VPP and IPP of 418 
4.37 and 3.27 after fermentation with PRA205 and PRA331, respectively. This could be related 419 
either to the specificity of the cell envelope proteinases and/or endopeptidases on caseins or to the 420 
higher intake of IPP compared to VPP through the peptide transport system in lactobacilli.  421 
Several clinical studies on hypertensive subjects showed that the administration of VPP and IPP via 422 
fermented milk has positive effects on blood pressure (Boelsma and Kloek, 2010; Nakamura et al., 423 
2011, Cicero et al., 2013). Daily doses (150 ml portion) of VPP/IPP in the range of 2-6 mg were 424 
associated with a decrease of the blood pressure between 1.5 and 10 mmHg (Seppo et al., 2003; 425 
Cicero et al., 2013). After 111 h of incubation, milk fermented with strain PRA205 contained 426 
concentrations of VPP/IPP equal to about 40.2 mg/L, corresponding to about 6 mg in 150 mL. In 427 
milk fermented with strain PRA331, the maximum VPP/IPP concentration (15.5 mg/L after 87 h of 428 
fermentation) corresponds to about 2.3 mg in 150 mL. Therefore, 150 mL portions of milk 429 
fermented with PRA331 or, especially, with PRA205, could correspond to doses which have in vivo 430 
hypotensive effect.  431 
In conclusion, the strains selected in the present study, and in particular Lb. casei PRA205, are able 432 
to produce, during milk fermentation, amounts of antihypertensive peptides (VPP and IPP) at doses 433 
able to reduce blood pressure in hypertensive subjects in vivo. To the best of our knowledge, this is 434 
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the first evidence that Lb. casei and Lb. rhamnosus strains are able to synthesize amounts of VPP 435 
and IPP comparable to those released by Lb. helveticus from milk proteins. Lb. casei PRA205 has 436 
been previously demonstrated to have high resistance to GI tract, antibiotic susceptibility, and 437 
adhesive phenotype (Solieri et al., 2014). These evidences overall suggest that Lb. casei PRA205 438 
may be a promising culture to produce functional milk with high amounts of VPP and IPP, 439 
antioxidant activities, and high content in health-promoting viable cells. 440 
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Figure Captions 
 
Figure 1. Screening of Lactobacillus casei (grey bars), Lactobacillus rhamnosus (white bars) and 
Lactobacillus paracasei (black bars) strains based on proteolytic activity after 72 h of inoculation in 
UHT skimmed milk. The extent of proteolysis is expressed as mmol/L leucin equivalents. Values of 
leucine equivalents (mmol/L) are normalized with respect to negative control (1.22 mmol/L). Data 
are represented by the mean (n = 3); error bars show standard deviation. 
Figure 2. Relative quantification (expressed as area under the peak, AUP) of Val-Pro-Pro (VPP) 
(white) and Ile-Pro-Pro (IPP) (black) released by 12 pre-selected lactobacilli after 72 h of 
inoculation in UHT skimmed milk. Lr, Lactobacillus rhamnosus; Lp, Lactobacillus paracasei; Lc, 
Lactobacillus casei. 
Figure 3. Kinetics of acidification (open symbols) and lactic acid production (solid symbols) in 
milk fermented with Lactobacillus casei PRA205 (circles) and Lactobacillus rhamnosus PRA331 
(squares). Data are represented by the mean (n = 3); error bars show standard deviation. * means 
P<0.05 respect to the previous time in the same strain; # means P<0.05 respect to the strain 
PRA331. 
Figure 4. Proteolytic (A) and radical scavenging (B) activities  measured during fermentation of 
milk with Lactobacillus casei PRA205 (circles) and Lactobacillus rhamnosus PRA331 (squares). 
Proteolysis activity is expressed as mmol/L of leucine equivalents, whereas radical scavenging 
activity as µmol/L of Trolox. Data are represented by the mean (n = 3); error bars show standard 
deviation. * means P<0.05 respect to the previous time in the same strain; # means P<0.05 respect 
to the strain PRA331. 
Figure 5. Angiotensin converting enzyme (ACE) inhibition activity (ACEi%) of milk samples 
fermented with Lactobacillus casei PRA205 (white) and Lactobacillus rhamnosus PRA331 (black) 
at different sampling times. Data are represented by the mean (n = 3); error bars show standard 
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deviation. * means P<0.05 respect to the previous time in the same strain; # means P<0.05 respect 
to the strain PRA331. 
Figure 6. Release of Val-Pro-Pro (VPP; panel A) and Ile-Pro-Pro (IPP; panel B) by Lactobacillus 
casei PRA205 (circles) and Lactobacillus rhamnosus PRA331 (squares) during milk fermentation. 
Data are represented by the mean (n = 3); error bars show standard deviation. * means P<0.05 
respect to the previous time in the same strain; # means P<0.05 respect to the strain PRA331. 
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Table 1. 
Species Strains  Isolation source References  
    
Lb. rhamnosus GG (ATCC 53103) faecal human sample Goldin et al., 1992 
 PRA101 6 month long ripened PR Solieri et al., 2012 
 PRA251, PRA321 7 month long ripened PR 
 PRA202, PRA211, PRA222 10 month long ripened PR 
 PRA231, PRA331 11 month long ripened PR 
 PRA011, PRA141, PRA152, PRA161, 
PRA172 
12 month long ripened PR 
 PRA091 14 month long ripened PR 
 PRA272 18 month long ripened PR 
 PRA291 23 month long ripened PR 
 LOC5, LOC6, LOC12, LOC46 human vagina samples provided by C. Randazzo 
 E24, E31, E33, D21, D55 Sicilian Pecorino cheeses Randazzo et al., 2006 
    
Lb. paracasei PRA104 6 month long ripened PR Solieri et al., 2012 
 PRA191, PRA213, PRA221 10 month long ripened PR 
 PRA181 11 month long ripened PR 
 PRA021, PRA071, PRA081, PRA171, 
PRA313, PRA111, PRA121, PRA131, 
PRA142 
12 month long ripened PR 
 PRA241 13 month long ripened PR 
   
Lb. casei PRA322 7 month long ripened PR Solieri et al., 2012 
 PRA205 10 month long ripened PR  
 PRA041 12 month long ripened PR  
    
Abbreviations: ATCC, American Type Culture Collection; PR, Parmigiano Reggiano cheese. 
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